Gregory Austin’s Post

"Part of what I learned was big thinking, and this comes from Stéphane Bancel. If you're gonna do it, go big. Go big or go home." 🚀 In Part 3 of The Biotech Startups Podcast, I sat down with Barry Ticho MD, PhD, founder of Verve Therapeutics and Chief Medical Officer at Stoke Therapeutics, who shared powerful insights about thinking big and making bold moves in drug development. In this episode, we dive deep into: – The surprising revelation that industry research is more rigorous than academic research, with higher reproducibility standards and quality control 🔬 🧬 – The evolution of clinical development and how it's becoming increasingly complex - from a 90% failure rate to billion-dollar investments spanning a decade 💰 – The critical importance of patient input in drug development and how it's revolutionizing the way we approach medicine creation 🏥 – The power of agility in biotech, and knowing when to pivot versus when to persist with your technology 🏃🏃♀️💨 – The essential elements of success in biotech: financial stability, maintaining good health, and being ready for transformative opportunities 💡 Barry offers invaluable insights into what it takes to succeed in modern drug development and the courage needed to pursue ambitious goals in biotech. Don't sleep on this episode! It's a true Masterclass. Apple Podcasts & Spotify links in the comments below 👇🏽 #biotechnology #lifesciences #podcast

Fractional expertise is powerful!

Opyl (ASX: OPL) Executive Chairman, Saurabh Jain, recently appeared on the Big Performance Podcast with Alex Elish. Listen now to gain insights into Saurabh’s journey from software engineer to leading multiple tech startups and becoming a CEO of a publicly listed company. 🔈 Listen now: https://lnkd.in/gN6d7y6Z In the episode, Saurabh discusses how his diverse experience uniquely positions him to lead Opyl and TrialKey, focusing on AI-driven innovations in clinical trials. TrialKey’s AI models predict trial success with up to 90% accuracy by analysing data from over 350,000 trials, enhancing efficiency and cost-effectiveness for pharmaceutical companies. Saurabh also highlights his leadership approach, including his commitment to meditation, which enhances his focus and stress management. For marketing, guest appearances, and investor enquiries: bernice.averion@opyl.ai Book a TrialKey demo: https://lnkd.in/g9rJtUBm #ai #clinicaltrials #leadership #biotech #podcast #pharmaceuticals #innovation #medtech #opylai #trialkeyai #medicalresearch #medicalinnovation

In the latest episode of the #ParexelBiotech podcast series, “De-Risking Drug Development,” our host, Paul Bridges, and colleagues focus on critical decision points in phases IIb & III that can ultimately determine the success of your product. Join Sangeeta Budhia, Sinan B. Sarac (MD, MSc, PhD), and Amy Pace as they discuss how to accelerate development and opportunities to differentiate your product through innovative and adaptive trial designs. Learn about the importance of integrated evidence planning and the critical role of early value story development alongside target product profile (TPP) planning. Mitigate development risks and stand out among competitors by planning ahead. Listen here: https://lnkd.in/g9Kt5hGA #Biotech #TrialDesign #ClinicalDevelopment

What a fascinating conversation on applications for #artificialintelligence in #biotech/techbio with Foresite Labs' Vik Bajaj. We cover the justification for his part in a $1B startup called Xaira Therapeutics, its place on the widening AI-empowered bio landscape, data limitations and how they're solved, and so much more. Tune into the videocast here, or listen and subscribe wherever you get your podcasts. https://lnkd.in/efb-bMZB Life Science Connect Bioprocess Online Life Science Leader

The role of IT has shifted from being a back-office function to a driver of business strategy. On the latest episode of the Biotech Bytes Podcast I was joined by Ganesh Iyer, Chief Information Officer at Harmony Biosciences. We discussed how programming knowledge serves as foundational but not always as a career endpoint, the role of technologists as change agents, and the need for balance between routine work and innovation. Whether you aim to transition into leadership, understand technology's role in business better, or grasp how to implement AI effectively, this episode is packed with insights. Tune in now! 👉 https://lnkd.in/etVn4auA #podcast #biotech #pharmaceutical #IT #AI #innovation #leadership #businessstrategy #businesssuccess

The role of IT has shifted from being a back-office function to a driver of business strategy. On the latest episode of the Biotech Bytes Podcast I was joined by Ganesh Iyer, Chief Information Officer at Harmony Biosciences. We discussed how programming knowledge serves as foundational but not always as a career endpoint, the role of technologists as change agents, and the need for balance between routine work and innovation. Whether you aim to transition into leadership, understand technology's role in business better, or grasp how to implement AI effectively, this episode is packed with insights. Tune in now! 👉 https://lnkd.in/e2S6BXFn #podcast #biotech #pharmaceutical #IT #AI #innovation #leadership #businessstrategy #businesssuccess

Part 1 of The Biotech Startups Podcast conversation with Meliora Therapeutics CEO, David Li, is now live, and it’s a crash course in understanding the virtuous relationship between the scientific and business aspects of running a biotech. – Lessons from Penn’s Vagelos Life Sciences & Management Program, a pre-Kite Pharma internship with Arie Belldegrun, MD, and maximizing patient and clinical impact – What it takes to get a drug financed, how business decisions impact stakeholders, from employees to patients, and getting a hands-on appreciation for the business side of life sciences at Goldman Sachs – The virtuous cycle of patient impact at scale through value creation for investors (these are absolutely inseparable if you want to maximize your biotech’s clinical impact) – Strategic program selection, finding market fit, building financial models for cashflow It’s another must-listen episode for anyone who wants to understand more about the business of biotech. Head over to Apple Podcasts or Spotify for this episode and more stories only a biotech exec can tell! #biotechnology #lifesciences #podcast

🚀 Big News: My New Podcast "Leading Beyond the Lab" is Coming Soon! 🎙️ I’m thrilled to share that I’m launching a podcast: Leading Beyond the Lab! This is something I’ve wanted to do for a while—to bring real, unfiltered insights from the drug development world to all of you who share my passion for this industry. Over the years, I’ve had countless chats with CMOs, CSOs, CEOs, Founders, HR Heads, and Investors, and some of their stories and lessons are too good not to share. Here’s a taste of what we’ll dive into: 🔥 How good drug development becomes great (and what sometimes holds it back) 🔥 The realities for Scientists and Physicians going from Academia, and moving into industry 🔥 Industry trends and what they really mean for us 🔥 What makes great leadership in this environment 🔥 Tough times and lessons learned from leaders who’ve been through it 🔥 Fundraising challenges in today’s climate for early stage biotechs — and how to navigate them The past few years have shown how much we can achieve when we work together (think Covid Vaccine!), and I’m hoping this podcast will bring that same spirit of collaboration! Stay tuned for updates —exciting things ahead! 👀 #ARTO #LeadingBeyondTheLab #PodcastComingSoon #DrugDevelopment #Biotech #Innovation #clinicaldevelopment #medicalaffairs #biotech

Join Rahul Chaturvedi for a conversation with Bharatt Chowrira, CEO, and Eric Elenko, Co-Founder & President, of PureTech Health, on a new episode of Biotech2050. Bharatt and Eric dive deep into PureTech’s R&D model—one that prioritizes solving specific problems over traditional approaches. They share their professional journeys, emphasizing the power of simplicity, persistence, and patient-centered innovation. The discussion includes a look at the rise of Karuna Therapeutics, a PureTech-founded company, and its journey to developing a transformative schizophrenia treatment. Tune in for valuable insights into the future of drug development, the need for more efficient pathways, and an exciting glimpse at what’s next for PureTech. #Clora #biotech #podcast #drugdevelopment #innovation #schizophrenia